Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 14.74M | 622.00K | 240.00K | 934.00K | 605.00K |
Gross Profit | -2.81M | 622.00K | -23.95M | 934.00K | -8.54M |
EBITDA | -241.76M | -436.18M | -335.51M | -315.38M | -187.93M |
Net Income | -413.56M | -583.20M | -417.32M | -349.85M | -224.19M |
Balance Sheet | |||||
Total Assets | 382.93M | 504.45M | 362.36M | 468.91M | 221.38M |
Cash, Cash Equivalents and Short-Term Investments | 149.81M | 266.46M | 107.18M | 317.12M | 96.06M |
Total Debt | 504.17M | 726.72M | 723.77M | 645.66M | 275.55M |
Total Liabilities | 871.06M | 1.09B | 812.18M | 712.82M | 339.87M |
Stockholders Equity | -488.13M | -586.99M | -447.33M | -242.17M | -119.81M |
Cash Flow | |||||
Free Cash Flow | -398.12M | -397.34M | -436.90M | -307.98M | -173.39M |
Operating Cash Flow | -391.24M | -366.76M | -337.51M | -274.42M | -171.72M |
Investing Cash Flow | -12.25M | -30.47M | 27.30M | -84.89M | -19.81M |
Financing Cash Flow | 281.63M | 558.34M | 233.61M | 505.44M | 150.68M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | $2.56B | 13.38 | 29.11% | ― | 29.97% | 178.11% | |
64 Neutral | $1.77B | ― | -5.78% | ― | 25.50% | 64.63% | |
56 Neutral | $2.11B | ― | -38.04% | ― | -82.38% | -164.76% | |
54 Neutral | $1.79B | ― | -70.58% | ― | 100.03% | 64.22% | |
52 Neutral | $7.61B | 0.11 | -63.03% | 2.07% | 16.35% | 0.29% | |
52 Neutral | $2.66B | ― | 78.99% | ― | 10238.41% | 47.67% | |
45 Neutral | $3.13B | ― | -62.46% | ― | ― | -43.10% |
On July 24, 2025, ImmunityBio, Inc. announced a securities purchase agreement to sell 29,629,632 shares of its common stock and warrants for an additional 29,629,632 shares, generating approximately $80 million in gross proceeds. The offering is expected to close around July 28, 2025, with Piper Sandler & Co. as the exclusive placement agent. In its Q2 2025 financial results, ImmunityBio reported a 60% increase in revenue to $26.4 million, driven by strong sales of ANKTIVA in BCG-unresponsive bladder cancer. The company also highlighted significant clinical progress, including the initiation of a randomized trial for lung cancer and regulatory discussions on lymphopenia and papillary NMIBC treatments.
The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
On June 18, 2025, ImmunityBio, Inc. held its Annual Meeting of Stockholders, where the 2025 Equity Incentive Plan was approved, replacing the 2015 Plan. This strategic move aims to better compete for and motivate key talent through equity-based awards, aligning the interests of employees and stockholders. Additionally, eight directors were re-elected, and Deloitte & Touche LLP’s appointment as the independent registered public accounting firm for 2025 was ratified.
The most recent analyst rating on (IBRX) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.